Takeda Pharmaceutical Co Ltd ADR (TAK) is next scheduled to report earnings on Jul 30, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $0.41.
Equity Rank's fundamental strength composite scores TAK at 61.2/100 (B-, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +33.0% per year and gross margin has moved -18.1 pp. Its SAVE composite score has moved -3.4 over the past 30 days.
Takeda Pharmaceutical Co Ltd ADR (TAK) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator